This website is for UK Healthcare Professionals only

This promotional website is for UK healthcare professionals involved in the care of patients with cancer. Adverse event reporting information can be found below.

On demand: CLL treatment sequencing content post EHA 2023

Dr Toby Eyre 

CLL-13 overview

Dr Toby Eyre provides a bite-sized summary of the 3-year data from CLL-13 and what the findings mean for fit, previously untreated patients 

Dr Toby Eyre

Venetoclax CLL-14 Data - An overview of 6-year follow-up

Watch Dr Toby Eyre (Oxford) as he examines the long-term evidence showing durable responses to venetoclax-based therapy in unfit, previously untreated patients, 5 years off therapy.

Dr Toby Eyre 

Update on Murano

In this video, Dr Toby Eyre discusses the final seven year follow-up data from the MURANO study, a global, phase III open-label, randomised study of patients with R/R CLL being treated with VenR compared to bendamustine with rituximab. 

On demand: Access content from BSH 2023

Dr Piers Patten

Take V - Take five for fitness

Does fitness in CLL need a rethink?

Panel discussion

Take V - Take five for fitness

Does fitness in CLL need a rethink?

Five-way panel discussion on rethinking fitness in CLL.
Chair - Dr Piers Patten
Panel - Dr Dima El-Sharkawi, Dr Ben Kennedy, Dr Tal Munir and Dr Renata Walewska


Adverse events should be reported. Reporting forms and information can be found at

Adverse events should also be reported to AbbVie on [email protected]

You are strongly advised to read the prescribing information and summary of product characteristics to evaluate patient suitability for Venclyxto.

UK-VNCCLL-230369. Date of preparation: November 2023